CpG-ODN作为免疫耐受诱导剂的研究进展

doi:10.12160/j.issn.1672-5190.2022.04.004

Abstract

Abstract:

Immunoglobulin E （IgE） - mediated allergic disorders can be treated with allergen-specific immunotherapy （ASIT）. Adjuvants and immunomodulators were utilized by researchers to improve the efficacy and safety of ASIT. CpG-oligodeoxynucleotide （CpG-ODN） is one of the best immunomodulators for the treatment of allergic disorders due to its ability to promote immunological tolerance. The doses of CpG-ODN were found to be critical for promoting immune regulation through the recruitment of plasmacytoid dendritic cells （pDCs）. Low doses of CpG-ODN elicited inflammatory responses while high doses of CpG-ODN triggered immunological tolerance. CpG-ODN has potential for the prevention and treatment of IgE-mediated allergic disorders. This paper reviews the research progress of the types of CpG-ODN, their effects on immune cells, and the mechanism of CpG-ODN as ASIT immunological tolerance inducer, in hoping to serve as references for related researches.

Key words: allergen-specific immunotherapy, CpG-oligodeoxynucleotide, allergy, immunological tolerance

CLC Number:

S852.4

LI Xiao-qi, LI Lin, JIA Shu-ping, WANG Feng-wu. Research Progress of CpG-ODN as Immunological Tolerance Inducer[J]. Animal Husbandry and Feed Science, 2022, 43(4): 19-24.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal30.magtechjournal.com/xmysl/EN/10.12160/j.issn.1672-5190.2022.04.004

https://journal30.magtechjournal.com/xmysl/EN/Y2022/V43/I4/19

References 27

[1]	BLUESTONE J A. Mechanisms of tolerance[J]. Immunological Reviews, 2011, 241(1):5-19. doi: 10.1111/j.1600-065X.2011.01019.x pmid: 21488886
[2]	GIARDINO G, GALLO V, PRENCIPE R, et al. Unbalanced immune system:Immunodeficiencies and autoimmunity[J]. Frontiers in Pediatrics, 2016, 4:107.
[3]	COX L. The role of allergen immunotherapy in the management of allergic rhinitis[J]. American Journal of Rhinology and Allergy, 2016, 30(1):48-53. doi: 10.2500/ajra.2016.30.4253 pmid: 26867530
[4]	WARREN C M, JIANG J L, GUPTA R S. Epidemiology and burden of food allergy[J]. Current Allergy and Asthma Reports, 2020, 20(2):6. doi: 10.1007/s11882-020-0898-7 pmid: 32067114
[5]	BRUNELLO L. Atopic dermatitis[J]. Nature Reviews Disease Primers, 2018, 4(1):2. doi: 10.1038/s41572-018-0004-9 pmid: 29930279
[6]	CHONG K W, RUIZ-GARCIA M, PATEL N, et al. Reaction phenotypes in IgE-mediated food allergy and anaphylaxis[J]. Annals of Allergy Asthma and Immunology, 2020, 124(5):473-478. doi: S1081-1206(19)31530-3 pmid: 31923546
[7]	FLEMING L, HEANEY L. Severe asthma-perspectives from adult and pediatric pulmonology[J]. Frontiers in Pediatrics, 2019, 7:389. doi: 10.3389/fped.2019.00389 pmid: 31649906
[8]	KOUZAKI H, ARIKATA M, KOJI M, et al. Dynamic change of anti-inflammatory cytokine IL-35 in allergen immune therapy for Japanese cedar pollinosis[J]. Allergy, 2019, 75(4):981-983. doi: 10.1111/all.v75.4
[9]	HARJUNPAA H, GUILLEREY C. TIGIT as an emerging immune checkpoint[J]. Clinical and Experimental Immunology, 2019, 200(2):108-119. doi: 10.1111/cei.13407
[10]	BABA Y, SASITO Y, KOTETSU Y. Heterogeneous subsets of B-lineage regulatory cells (Breg cells)[J]. International Immunology, 2020, 32(3):155-162. doi: 10.1093/intimm/dxz068 pmid: 31630184
[11]	BOONPIYATHAD T, VAN De VEEN W, WIRZ O, et al. Role of Der p 1-specific B cells in immune tolerance during 2 years of house dust mite-specific immunotherapy[J]. Journal of Allergy and Clinical Immunology, 2019, 143(3):1077-1086. doi: 10.1016/j.jaci.2018.10.061
[12]	ORENGO J M, RADIN A R, KAMAT V, et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement[J]. Nature Communications, 2018, 9(1):1421. doi: 10.1038/s41467-018-03636-8 pmid: 29650949
[13]	SIRVENT S, SORIA I, CIRAUQUI C, et al. Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1[J]. Journal of Allergy and Clinical Immunology, 2016, 138(2):121-129.
[14]	LI T T, WU J, ZHU S, et al. A novel C type CpG oligodeoxynucleotide exhibits immunostimulatory activity in vitro and enhances antitumor effect in vivo[J]. Frontiers in Pharmacology, 2020, 11:8. doi: 10.3389/fphar.2020.00008
[15]	ZHOU Y F, FANG L, PENG L S. TLR9 and its signaling pathway in multiple sclerosis[J]. Journal of the Neurological Sciences, 2017, 373:95-99. doi: S0022-510X(16)30821-8 pmid: 28131238
[16]	HU W, JAIN A, GAO Y J, et al. Differential outcome of TRIF-mediated signaling in TLR4 and TLR3 induced DC maturation[J]. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112(45):13994-13999. doi: 10.1073/pnas.1510760112 pmid: 26508631
[17]	HUHTA H, HELMINEN O, KAUPPILA J H, et al. The expression of toll-like receptors in normal human and murine gastrointestinal organs and the effect of microbiome and cancer[J]. Journal of Histochemistry and Cytochemistry, 2016, 64(8):470-482. doi: 10.1369/0022155416656154 pmid: 27370795
[18]	MANANGEESWARAN M, LEWKOWICZ A P, ISRAELY T, et al. CpG oligonucleotides protect mice from alphavirus encephalitis:Role of NK cells,interferons,and TNF[J]. Frontiers in Immunology, 2020, 11:237. doi: 10.3389/fimmu.2020.00237
[19]	GUDJONSON H, PRITYKIN Y, DEEP D, et al. Transcriptional basis of mouse and human dendritic cell heterogeneity[J]. Cell, 2019, 179(4):846-863. doi: S0092-8674(19)31116-X pmid: 31668803
[20]	FUCIKOVA J, PALOVA-JELINKOVA L, BARTUNKOVA J. Induction of tolerance and immunity by dendritic cells:Mechanisms and clinical applications[J]. Frontiers in Immunology, 2019, 10:2393. doi: 10.3389/fimmu.2019.02393
[21]	AUDIGER C, RAHMAN M J, YUN T J, et al. The importance of dendritic cells in maintaining immune tolerance[J]. The Journal of Immunology, 2017, 198(6):2223-2231.
[22]	MIROTTI L, ALBERCA C R W, GOMES E, et al. CpG-ODN shapes Alum adjuvant activity signaling via MyD88 and IL-10[J]. Frontiers in Immunology, 2017, 8:47.
[23]	KONKEL J E, ZHANG D, ZANVIT P, et al. Transforming growth factor-beta signaling in regulatory T Cells controls T helper-17 cells and tissue-specific immune responses[J]. Immunity, 2017, 46(4):660-674. doi: 10.1016/j.immuni.2017.03.015
[24]	DUPAGE M, BLUESTONE J A. Harnessing the plasticity of CD4⁺ T cells to treat immune-mediated disease[J]. Nature Reviews Immunology, 2016, 16(3):149-163. doi: 10.1038/nri.2015.18
[25]	WANG M, TAN G, ELJASZEWICZ A, et al. Laundry detergents and detergent residue after rinsing directly disrupt tight junction barrier integrity in human bronchial epithelial cells[J]. Journal of Allergy and Clinical Immunology, 2019, 143(5):1892-1903. doi: 10.1016/j.jaci.2018.11.016
[26]	SCHLEIMER R P, BERDNIKOVS S. Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases[J]. Journal of Allergy and Clinical Immunology, 2017, 139(6):1752-1761. doi: 10.1016/j.jaci.2017.04.010
[27]	KUBO T, WAWRZYNIAK P, MORITA H, et al. CpG DNA enhances the tight junction integrity of the bronchial epithelial cell barrier[J]. Journal of Allergy and Clinical Immunology, 2015, 136(5):1413-1416. doi: 10.1016/j.jaci.2015.05.006

Research Progress of CpG-ODN as Immunological Tolerance Inducer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 27

Related Articles 1

Recommended Articles

Metrics

Comments